CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice
作者:
  • WillekedeHaan,JitskedeVries-vanderWeij,CarolineC.vanderHoogt,JoséW.A.vanderHoorn,JohannesA.Romijn,J.WouterJukema,LouisM.Havekes,HansM.G.Princen,PatrickC.N.Rensen

    WillekedeHaan,JitskedeVries-vanderWeij,CarolineC.vanderHoogt,JoséW.A.vanderHoorn,JohannesA.Romijn,J.WouterJukema,LouisM.Havekes,HansM.G.Princen,PatrickC.N.Rensen

    DepartmentsofGeneralInternalMedicine,Endocrinology,andMetabolicDiseases;Leiden,TheNetherlands;DepartmentsofHumanGenetics;Leiden,TheNetherlands;TNO-Biosciences,GaubiusLaboratory;Leiden,TheNetherlands;DepartmentsofGeneralInternalMedicine,Endocrinology,andMetabolicDiseases;Leiden,TheNetherlands;DepartmentsofCardiology,LeidenUniversityMedicalCenter;Leiden,TheNetherlands;TNO-Biosciences,GaubiusLaboratory;Leiden,TheNetherlands;DepartmentsofGeneralInternalMedicine,Endocrinology,andMetabolicDiseases;Leiden,TheNetherlands;DepartmentsofCardiology,LeidenUniversityMedicalCenter;Leiden,TheNetherlands;DepartmentsofGeneralInternalMedicine,Endocrinology,andMetabolicDiseases;Leiden,TheNetherlands;DepartmentsofCardiology,LeidenUniversityMedicalCenter;Leiden,TheNetherlands;TNO-Biosciences,GaubiusLaboratory;Leiden,TheNetherlands;TNO-Biosciences,GaubiusLaboratory;Leiden,TheNetherlands;DepartmentsofGeneralInternalMedicine,Endocrinology,andMetabolicDiseases;Leiden,TheNetherlands
    在知网中查找
    在百度中查找
    在本站中查找

CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice
Author:
  • 摘要
  • | |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
    摘要:

    Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

    Abstract:

    Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

    参考文献
    相似文献
    引证文献
引用本文

WillekedeHaan, JitskedeVries-vanderWeij, CarolineC. vanderHoogt, JoséW. A. vanderHoorn, JohannesA. Romijn, J. WouterJukema, LouisM. Havekes, HansM. G. Princen, PatrickC. N. Rensen. CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice[J].中国动脉硬化杂志,2009,17(7):574~575.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史